Upgrades
According to Goldman Sachs, the prior rating for FREYR Battery (NYSE:FREY) was changed from Neutral to Buy. In the second quarter, FREYR Battery showed an EPS of $0.24, compared to $0.04 from the year-ago quarter. At the moment, the stock has a 52-week-high of $13.54 and a 52-week-low of $6.42. FREYR Battery closed at $10.57 at the end of the last trading period.
Berenberg upgraded the previous rating for Kosmos Energy Ltd (NYSE:KOS) from Hold to Buy. In the second quarter, Kosmos Energy showed an EPS of $0.28, compared to $0.03 from the year-ago quarter. The current stock performance of Kosmos Energy shows a 52-week-high of $8.48 and a 52-week-low of $3.45. Moreover, at the end of the last trading period, the closing price was at $6.77.
B of A Securities upgraded the previous rating for Dream Finders Homes Inc (NASDAQ:DFH) from Underperform to Neutral. For the second quarter, Dream Finders Homes had an EPS of $0.60, compared to year-ago quarter EPS of $0.31. The stock has a 52-week-high of $23.09 and a 52-week-low of $9.60. At the end of the last trading period, Dream Finders Homes closed at $11.43.
According to Morgan Stanley, the prior rating for Stride Inc (NYSE:LRN) was changed from Equal-Weight to Overweight. For the fourth quarter, Stride had an EPS of $0.66, compared to year-ago quarter EPS of $0.25. The current stock performance of Stride shows a 52-week-high of $44.93 and a 52-week-low of $25.65. Moreover, at the end of the last trading period, the closing price was at $35.52.
Stifel upgraded the previous rating for Verve Therapeutics Inc (NASDAQ:VERV) from Hold to Buy. For the second quarter, Verve Therapeutics had an EPS of $0.84, compared to year-ago quarter EPS of $6.66. The stock has a 52-week-high of $41.30 and a 52-week-low of $10.70. At the end of the last trading period, Verve Therapeutics closed at $40.12.
See all analyst ratings upgrades.
Downgrades
For GDS Holdings Ltd (NASDAQ:GDS), Daiwa Capital downgraded the previous rating of Outperform to Hold. For the second quarter, GDS Holdings had an EPS of $0.32, compared to year-ago quarter EPS of $0.28. The current stock performance of GDS Holdings shows a 52-week-high of $48.42 and a 52-week-low of $19.83. Moreover, at the end of the last trading period, the closing price was at $26.91.
According to B of A Securities, the prior rating for Toll Brothers Inc (NYSE:TOL) was changed from Buy to Neutral. In the third quarter, Toll Brothers showed an EPS of $2.35, compared to $1.87 from the year-ago quarter. The current stock performance of Toll Brothers shows a 52-week-high of $72.75 and a 52-week-low of $40.20. Moreover, at the end of the last trading period, the closing price was at $46.22.
For GDS Holdings Ltd (NASDAQ:GDS), Deutsche Bank downgraded the previous rating of Buy to Hold. In the second quarter, GDS Holdings showed an EPS of $0.32, compared to $0.28 from the year-ago quarter. At the moment, the stock has a 52-week-high of $48.42 and a 52-week-low of $19.83. GDS Holdings closed at $26.91 at the end of the last trading period.
According to B of A Securities, the prior rating for KB Home (NYSE:KBH) was changed from Buy to Neutral. For the second quarter, KB Home had an EPS of $2.32, compared to year-ago quarter EPS of $1.50. The current stock performance of KB Home shows a 52-week-high of $50.20 and a 52-week-low of $24.78. Moreover, at the end of the last trading period, the closing price was at $30.26.
B of A Securities downgraded the previous rating for Lennar Corp (NYSE:LEN) from Neutral to Underperform. Lennar earned $4.69 in the second quarter, compared to $2.95 in the year-ago quarter. At the moment, the stock has a 52-week-high of $116.36 and a 52-week-low of $62.54. Lennar closed at $83.80 at the end of the last trading period.
For GDS Holdings Ltd (NASDAQ:GDS), JP Morgan downgraded the previous rating of Overweight to Neutral. GDS Holdings earned $0.32 in the second quarter, compared to $0.28 in the year-ago quarter. The current stock performance of GDS Holdings shows a 52-week-high of $48.42 and a 52-week-low of $19.83. Moreover, at the end of the last trading period, the closing price was at $26.91.
According to Raymond James, the prior rating for La-Z-Boy Inc (NYSE:LZB) was changed from Outperform to Market Perform. La-Z-Boy earned $0.91 in the first quarter, compared to $0.55 in the year-ago quarter. The current stock performance of La-Z-Boy shows a 52-week-high of $38.16 and a 52-week-low of $22.21. Moreover, at the end of the last trading period, the closing price was at $29.18.
For Akerna Corp (NASDAQ:KERN), HC Wainwright & Co. downgraded the previous rating of Buy to Neutral. For the second quarter, Akerna had an EPS of $0.15, compared to year-ago quarter EPS of $0.27. The current stock performance of Akerna shows a 52-week-high of $1.92 and a 52-week-low of $0.12. Moreover, at the end of the last trading period, the closing price was at $0.13.
According to Goldman Sachs, the prior rating for Krystal Biotech Inc (NASDAQ:KRYS) was changed from Buy to Neutral. Krystal Biotech earned $1.10 in the second quarter, compared to $0.74 in the year-ago quarter. The stock has a 52-week-high of $85.11 and a 52-week-low of $47.67. At the end of the last trading period, Krystal Biotech closed at $76.81.
Goldman Sachs downgraded the previous rating for Edgewise Therapeutics Inc (NASDAQ:EWTX) from Neutral to Sell. In the second quarter, Edgewise Therapeutics showed an EPS of $0.32, compared to $0.21 from the year-ago quarter. The current stock performance of Edgewise Therapeutics shows a 52-week-high of $20.71 and a 52-week-low of $5.41. Moreover, at the end of the last trading period, the closing price was at $11.02.
For Magenta Therapeutics Inc (NASDAQ:MGTA), Goldman Sachs downgraded the previous rating of Buy to Neutral. In the second quarter, Magenta Therapeutics showed an EPS of $0.29, compared to $0.32 from the year-ago quarter. At the moment, the stock has a 52-week-high of $5.49 and a 52-week-low of $0.92. Magenta Therapeutics closed at $1.94 at the end of the last trading period.
See all analyst ratings downgrades.
Initiations
With a Buy rating, JonesTrading initiated coverage on Satsuma Pharmaceuticals Inc (NASDAQ:STSA). The price target seems to have been set at $14.00 for Satsuma Pharmaceuticals. Satsuma Pharmaceuticals earned $0.52 in the second quarter, compared to $0.38 in the year-ago quarter. At the moment, the stock has a 52-week-high of $6.52 and a 52-week-low of $2.51. Satsuma Pharmaceuticals closed at $6.03 at the end of the last trading period.
With a Buy rating, JonesTrading initiated coverage on Impel Pharmaceuticals Inc (NASDAQ:IMPL). The price target seems to have been set at $26.00 for Impel Pharmaceuticals. In the second quarter, Impel Pharmaceuticals showed an EPS of $1.09, compared to $0.79 from the year-ago quarter. The current stock performance of Impel Pharmaceuticals shows a ...Full story available on Benzinga.com
Benzinga
Acadia Realty Trust
Alexander & Baldwin, Inc.
BRIXMOR PROPERTY GROUP INC.
Essential Properties Realty Trust, Inc.
Federal Realty Investment Trust
Gladstone Commercial Corporation - REIT
Kimco Realty Corp.
Regency Centers Corporation
Saul Centers, Inc.
UBRAN EDGE PROPERTIES